Molecular Evidence (rationale) for T cells targeted therapy in iMCD patients:
- Lymphocyte proliferation, including T cells, angiogenesis and lymphocyte activation (Thomson et al) are three hallmarks of Castleman disease.
Case Reports of anti-T cell therapy for iMCD patients:
Sirolimus (Rapamycin) is an mTOR inhibitor is thought to block lymphocyte (including T cell) proliferation, angiogenesis (through blocking VEGF expression) and lymphocyte activation. (Thomson et al)
- To learn more about sirolimus treatment for iMCD, please visit here.
Cyclosporin is a calcineurin inhibitor, which prevents T cell activation, and therefore serves as an immunosuppressant.
- To see case reports of cyclosporin monotherapy used to treat iMCD patients, please visit here.
Clinical Trials targeting T cells in iMCD:
No clinical trials targeting T cells in iMCD patients have been conducted